Truist Securities Reiterates Buy on Beta Bionics, Raises Price Target to $23
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $22 to $23.
Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $22 to $23.